Daewoong Pharmaceutical will receive government funding to establish production facilities for its Covid-19 treatment candidate. The company will receive a maximum 19 trillion won ($17.2 billion) from the Ministry of Health and Welfare by until 2021.
Samsung Biologics signed a contract development organization (CDO) deal with GeneQuantum, a Chinese biotech venture, the Korean company said Monday.
Orion Holdings, parent company of Choco Pie manufacturer Orion, made its first foray into the biopharmaceutical industry through a partnership with a state-run Chinese company.
Once the No. 2 company on the Kosdaq in terms of market capitalization, bio firm Helixmith is on the verge of being delisted after it lost a huge amount of money over the last five years through a series of risky investments.
In the early 2000s, Korea’s largest conglomerates Samsung, LG and SK were all executing massive investment plans in the field of biopharmaceuticals — a highly unfamiliar realm to Koreans at the time.
Samsung Biologics has signed a three-year supply deal worth $330.8 million with British pharmaceutical firm AstraZeneca. Under the contract deal, Samsung Biologics will produce drug substances and products for AstraZeneca through Dec. 2023.
Paris-based Sanofi has decided to drop ongoing Phase 3 clinical trials and marketing rights of Hanmi Pharmaceutical’s efpeglenatide, a diabetes drug.
Appointed in 2017, Managing and Representative Director Glenn Young is the first regional head at Merck Korea to come from a life sciences background, instead of materials which was the case for all his predecessors.
Korean biopharmaceutical firm Celltrion said Wednesday that its two kinds of diagnostic kits for the novel coronavirus began sales in the United States.
Samsung Biologics will build its largest factory in Songdo, Incheon, with an investment totaling 1.74 trillion won ($1.47 billion). This will be the company’s fourth plant, all in Incheon's Songdo District.